Targeting MicroRNAs: Promising Future Therapeutics in the Treatment of Allergic Airway Disease.
- Publisher:
- BEGELL HOUSE INC
- Publication Type:
- Journal Article
- Citation:
- Crit Rev Eukaryot Gene Expr, 2018, 28, (2), pp. 125-127
- Issue Date:
- 2018
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
| targeting microRNAs- promising future therapeutics in the treatment of allergic airway disease.pdf | Accepted version | 446.43 kB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
MicroRNAs (miRNAs) are short noncoding RNAs that control gene expression posttranscriptionally by directly blocking translation of their target mRNAs or by repressing protein production via mRNA destabilization. Investigations into miRNAs began approximately 12 years ago with their discovery in mammalian cells. Still, the involvement of miRNAs in the development of asthma remains unclear, and this topic needs further research to discover various molecular mechanisms responsible for the pathogenesis of asthma and new therapeutic interventions. So far, various miRNAs have been identified in allergic airway disease along with their targets. Our present mini-review highlights the latest information involving the role of miRNAs in asthma.
Please use this identifier to cite or link to this item: